Development of the global API market
Preliminary projections show that the global active pharmaceutical ingredients (API) market will reach $265.3 billion by 2026. The US market is estimated to be $71.5 billion in 2021, while China, the world's second largest economy, is expected to reach a market size of $35.4 billion by 2026, with a CAGR of 7.6% during the analysis period. China has always been the main producer and exporter of API, accounting for about 20% of the global API output, which cannot be separated from the support of national policies and the improvement of infrastructure, logistics and personnel. Apis are the main components of bioactive substances and drug manufacturing.
Global API production is mainly concentrated in developing countries because of the ability to scale up production based on customization and low-cost manufacturing. From the current market situation, the change of the overall environment and the increasing number of chronic diseases and tumor population make the domestic market cannot wait for the launch of the original drug. In many cases, in the case of cancer and cardiovascular disease, the demand is greater than the supply. With a long queue of generic and "blockbuster" drugs relying on THE API waiting for approval, the API market is only going to grow faster.
Post time: Jun-18-2022